

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification<sup>6</sup>:  
C12N 15/12, C07K 14/705, C12N 15/11,  
C12Q 1/68, A61K 48/00, C12N 5/10,  
C07K 16/18, G01N 33/53

A2

(11) International Publication Number: WO 97/00952

(43) International Publication Date: 9 January 1997 (09.01.97)

(21) International Application Number: PCT/US96/10618

(22) International Filing Date: 20 June 1996 (20.06.96)

(30) Priority Data:  
60/000,352 20 June 1995 (20.06.95) US  
08/567,817 6 December 1995 (06.12.95) US

(71) Applicant: INCYTE PHARMACEUTICALS, INC. [US/US];  
3174 Porter Drive, Palo Alto, CA 94304 (US).

(72) Inventors: COLEMAN, Roger; 260 Mariposa #2, Mountain View, CA 94041 (US). GUEGLER, Karl, J.; 1048 Oakland Avenue, Menlo Park, CA 94025 (US). AU-YOUNG, Janice; 1419 Kains Avenue, Berkeley, CA 94702 (US). BANDMAN, Olga; 2309 Rock Street #27, Mountain View, CA 94043 (US). SEILHAMER, Jeffrey, J.; 12555 La Cresta, Los Altos Hills, CA 94022 (US).

(74) Agent: GLAISTER, Debra, J.; Incyte Pharmaceuticals, Inc.,  
3174 Porter Drive, Palo Alto, CA 94304 (US).

(81) Designated States: AT, AU, BR, CA, CH, CN, DE, DK, ES, FI, GB, IL, JP, KR, MX, NO, NZ, RU, SE, SG, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

## Published

Without international search report and to be republished upon receipt of that report.

(54) Title: A HUMAN EDG-2 RECEPTOR HOMOLOG

## (57) Abstract

The present invention provides nucleic acid and amino acid sequences that identify and encode a novel EDG-2 receptor homolog (hedg) expressed in human rheumatoid synovium. The present invention also provides for probes for the detection of nucleotide sequences encoding of HEDG or HEDG-like molecules, antisense molecules to the nucleotide sequences which encode HEDG, diagnostic tests based on HEDG encoding nucleic acid molecules, genetically engineered expression vectors and host cells for the production of purified HEDG, antibodies capable of binding specifically to HEDG, and antagonists and inhibitors with specific binding activity for the polypeptide HEDG.

1 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## A HUMAN EDG-2 RECEPTOR HOMOLOG

### TECHNICAL FIELD

The present invention is in the field of molecular biology; more particularly, the present invention describes a nucleic acid sequence and an amino acid sequence for a novel human EDG-2 receptor homolog.

### BACKGROUND ART

The EDG-2 receptor is a putative G-protein coupled seven transmembrane receptor (T7G) which was initially cloned from sheep mRNA (GenBank U18405; Masana MI et al (1994) unpublished). Human edg-1 is commonly grouped with orphan receptors because its endogenous ligand is not known (Hla T and Maciag T (1990) J Biol Chem 265:9308-13). Several T7G receptors have been classified as orphan receptors; they include LCR-1 from brain, the mas oncogene associated with epidermoid carcinoma, RDC-1 known from several major organs, and R334 from rat brain and testis. In some of these cases, a ligand was initially proposed and has since been discounted. The orphan receptors vary in number of amino acids, in molecular weight, in glycosylation sites, and presence and number of disulfide bonds (Watson S and Arkinstall S (1994) The G-Protein Linked Receptor Facts Book, Academic Press, San Diego CA).

They are, however, related to other T7Gs by their seven hydrophobic domains which span the plasma membrane and form a bundle of antiparallel  $\alpha$  helices. These transmembrane segments (TMS) are designated by roman numerals I-VII and account for structural and functional features of the receptor. In most cases, the bundle of helices forms a binding pocket; however, when the binding site must accommodate more bulky molecules, the extracellular N-terminal segment or one or more of the three extracellular loops participate in binding and in subsequent induction of conformational change in intracellular portions of the receptor. The activated receptor, in turn, interacts with an intracellular G-protein complex which mediates further intracellular signalling activities generally the production of second messengers such as cyclic AMP (cAMP), phospholipase C, inositol triphosphate or ion channel proteins.

T7G receptors are expressed and activated during numerous developmental and disease processes. Identification of a novel T7G receptor provides the opportunity to diagnose or intervene in such processes, and the receptor can be used in screening assays to identify physiological or pharmaceutical molecules which trigger, prolong or inhibit its activity.

### DISCLOSURE OF THE INVENTION

The subject invention provides a unique nucleotide sequence which encodes a novel human EDG-2 receptor homolog (HEDG). The cDNA, herein designated hedg, was identified and cloned using Incyte Clone No. 80853 from a rheumatoid synovium cDNA library.

The invention relates to the use of nucleic acid and amino acid sequences of HEDG, or its variants, in the diagnosis or treatment of activated, inflamed or diseased cells and/or tissues associated with its expression. Aspects of the invention include the antisense DNA of hedg; cloning or expression vectors containing hedg; host cells or organisms transformed with expression vectors containing hedg; a method for the production and recovery of purified HEDG from host cells; and purified protein, HEDG, which can be used to identify inhibitors for the downregulation of signal transduction involving HEDG.

#### BRIEF DESCRIPTION OF DRAWINGS

Figures 1A and 1B shows the alignment of the nucleic acid sequence (coding region of SEQ ID NO: 1) and amino acid sequence (SEQ ID NO:2) for HEDG. The alignment of the sequences was produced using MacDNAsis software (Hitachi Software Engineering Co Ltd)

Figure 2 displays the alignment of HEDG with sheep EDG-2 (U18405; SEQ ID NO:3) and human EDG-1 (GI 119130; SEQ ID NO:4) receptors. Note the conserved Arg<sup>36</sup> and Ser<sup>37</sup> cleavage site characteristic of these T7G molecules. Sequences for Fig. 2 were aligned using the multisequence alignment program of DNASTar software (DNASTar Inc, Madison WI).

#### MODES FOR CARRYING OUT THE INVENTION

As used herein and designated by the upper case abbreviation, HEDG, refers to an EDG2 receptor homolog in either naturally occurring or synthetic form and active fragments thereof which have the amino acid sequence of SEQ ID NO:2. In one embodiment, the polypeptide HEDG is encoded by mRNAs transcribed from the cDNA, as designated by the lower case abbreviation, hedg, of SEQ ID NO:1.

The novel human edg-2 receptor homolog, HEDG, which is the subject of this patent application, was discovered among the partial cDNA sequences (Incyte Clone 80853) expressed in a rheumatoid synovium library. It is more distantly homologous to human edg-1 which was cloned from human vascular endothelial cells and expressed in epithelioid cells, fibroblasts, melanocytes, and vascular smooth muscle cells.

An "oligonucleotide" is a stretch of nucleotide residues which has a sufficient number of bases to be used as an oligomer, amplimer or probe in a polymerase chain reaction (PCR). Oligonucleotides are prepared from genomic or cDNA sequence and are used to amplify, reveal or confirm the presence of a similar DNA or RNA in a particular cell or tissue. Oligonucleotides or oligomers comprise portions of a DNA sequence having at least about 10 nucleotides and as many as about 35 nucleotides, preferably about 25 nucleotides.

"Probes" may be derived from naturally occurring or recombinant single- or double-stranded nucleic acids or be chemically synthesized. They are useful in detecting the presence of identical or similar sequences.

A "portion" or "fragment" of a polynucleotide or nucleic acid comprises all or any part of the nucleotide sequence having fewer nucleotides than about 6 kb, preferably fewer than about 1 kb which can be used as a probe. Such probes may be labelled with reporter molecules using, nick translation, Klenow fill-in reaction, PCR or other methods well known in the art.

5 After pretesting to optimize reaction conditions and to eliminate false positives, nucleic acid probes may be used in Southern, northern or in situ hybridizations to determine whether DNA or RNA encoding HEDG is present in a cell type, tissue, or organ.

"Reporter" molecules are those radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents which associate with, establish the presence of, and  
10 may allow quantification of a particular nucleotide or amino acid sequence.

"Recombinant nucleotide variants" encoding HEDG may be synthesized by making use of the "redundancy" in the genetic code. Various codon substitutions, such as the silent changes which produce specific restriction sites or codon usage-specific mutations, may be introduced to optimize cloning into a plasmid or viral vector or expression in a particular prokaryotic or  
15 eukaryotic host system, respectively.

"Chimeric" molecules may be constructed by introducing all or part of the nucleotide sequence of this invention into a vector containing additional nucleic acid sequence which might be expected to change any one (or more than one) of the following HEDG characteristics: cellular location, distribution, ligand-binding affinities, interchain affinities, degradation/turnover rate, signalling, etc.  
20

"Active" refers to those forms, fragments, or domains of any HEDG polypeptide which retain the biologic and/or antigenic activities of any naturally occurring HEDG.

"Naturally occurring HEDG" refers to a polypeptide produced by cells which have not been genetically engineered and specifically contemplates various polypeptides arising from post-translational modifications of the polypeptide including but not limited to acetylation, carboxylation, glycosylation, phosphorylation, lipidation and acylation.  
25

"Derivative" refers to those polypeptides which have been chemically modified by such techniques as ubiquitination, labelling (see above), pegylation (derivatization with polyethylene glycol), and chemical insertion or substitution of amino acids such as ornithine which do not normally occur in human proteins.  
30

"Recombinant polypeptide variant" refers to any polypeptide which differs from naturally occurring HEDG by amino acid insertions, deletions and/or substitutions, created using recombinant DNA techniques. Guidance in determining which amino acid residues may be replaced, added or deleted without abolishing activities of interest may be found by comparing the sequence of HEDG with that of related polypeptides and minimizing the number of amino acid  
35

sequence changes made in highly conserved regions.

Amino acid "substitutions" are conservative in nature when they result from replacing one amino acid with another having similar structural and/or chemical properties, such as the replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, or a threonine with a serine.

"Insertions" or "deletions" are typically in the range of about 1 to 5 amino acids. The variation allowed may be experimentally determined by producing the peptide synthetically or by systematically making insertions, deletions, or substitutions of nucleotides in the hedg sequence using recombinant DNA techniques.

A "signal or leader sequence" can be used, when desired, to direct the polypeptide through a membrane of a cell. Such a sequence may be naturally present on the polypeptides of the present invention or provided from heterologous sources by recombinant DNA techniques.

An "oligopeptide" is a short stretch of amino acid residues and may be expressed from an oligonucleotide. It may be functionally equivalent to and the same length as (or considerably shorter than) a "fragment," "portion," or "segment" of a polypeptide. Such sequences comprise a stretch of amino acid residues of at least about 5 amino acids and often about 17 or more amino acids, typically at least about 9 to 13 amino acids, and of sufficient length to display biologic and/or antigenic activity.

"Inhibitor" is any substance which retards or prevents a chemical or physiological reaction or response. Common inhibitors include but are not limited to antisense molecules, antibodies, and antagonists.

"Standard" expression is a quantitative or qualitative measurement for comparison. It is based on a statistically appropriate number of normal samples and is created to use as a basis of comparison when performing diagnostic assays, running clinical trials, or following patient treatment profiles.

"Animal" as used herein may be defined to include human, domestic (cats dogs, etc.), agricultural (cows, horses, sheep, etc) or test species (mouse, rat, rabbit, etc).

The present invention provides a nucleotide sequence uniquely identifying a novel seven transmembrane receptor, human EDG-2 or HEDG. Because HEDG is specifically expressed in inflamed rheumatoid synovium, the nucleic acids (hedg), polypeptides (HEDG) and antibodies to HEDG are useful in diagnostic assays which survey for increased receptor production.

Excessive expression of HEDG is likely to be associated with the activation of T lymphocytes and other cells which respond to inflammation and can result in the production of abundant proteases and other molecules which can lead to tissue damage or destruction. Therefore, a diagnostic test for excessive expression of HEDG can accelerate diagnosis and proper treatment

of abnormal conditions caused by viral, bacterial or fungal infections; allergic responses; mechanical injury associated with trauma; hereditary diseases; lymphoma or carcinoma; or other conditions which activate the genes of lymphoid tissues.

The nucleotide sequences encoding HEDG (or their complement) have numerous applications in techniques known to those skilled in the art of molecular biology. These techniques include use as hybridization probes, use in the construction of oligomers for PCR, use for chromosome and gene mapping, use in the recombinant production of HEDG, and use in generation of antisense DNA or RNA, their chemical analogs and the like. Uses of nucleotides encoding HEDG disclosed herein are exemplary of known techniques and are not intended to limit their use in any technique known to a person of ordinary skill in the art. Furthermore, the nucleotide sequences disclosed herein may be used in molecular biology techniques that have not yet been developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, e.g., the triplet genetic code, specific base pair interactions, etc.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of HEDG-encoding nucleotide sequences may be produced. Some of these will only bear minimal homology to the nucleotide sequence of the known and naturally occurring HEDG. The invention has specifically contemplated each and every possible variation of nucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the nucleotide sequence of naturally occurring hedg, and all such variations are to be considered as being specifically disclosed.

Although the nucleotide sequences which encode HEDG, its derivatives or its variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring hedg under stringent conditions, it may be advantageous to produce nucleotide sequences encoding HEDG or its derivatives possessing a substantially different codon usage. Codons can be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic expression host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding HEDG and/or its derivatives without altering the encoded aa sequence include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

Nucleotide sequences encoding HEDG may be joined to a variety of other nucleotide sequences by means of well established recombinant DNA techniques (Sambrook J et al (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor NY; or Ausubel FM et al (1989) Current Protocols in Molecular Biology, John Wiley & Sons,

New York City). Useful nucleotide sequences for joining to hedg include an assortment of cloning vectors such as plasmids, cosmids, lambda phage derivatives, phagemids, and the like. Vectors of interest include expression vectors, replication vectors, probe generation vectors, sequencing vectors, etc. In general, vectors of interest may contain an origin of replication functional in at least one organism, convenient restriction endonuclease sensitive sites, and selectable markers for one or more host cell systems.

Another aspect of the subject invention is to provide for hedg-specific hybridization probes capable of hybridizing with naturally occurring nucleotide sequences encoding HEDG. Such probes may also be used for the detection of similar T7G encoding sequences and should preferably contain at least 50% of the nucleotides from the hedg sequence. The hybridization probes of the subject invention may be derived from the nucleotide sequence presented as SEQ ID NO:1 or from genomic sequences including promoter, enhancers or introns of the native gene. Hybridization probes may be labeled by a variety of reporter molecules using techniques well known in the art.

PCR as described US Patent Nos. 4,683,195; 4,800,195; and 4,965,188 provides additional uses for oligonucleotides based upon the nucleotide sequence which encodes HEDG. Such probes used in PCR may be of recombinant origin, chemically synthesized, or a mixture of both. Oligomers may comprise discrete nucleotide sequences employed under optimized conditions for identification of hedg in specific tissues or diagnostic use. The same two oligomers, a nested set of oligomers, or even a degenerate pool of oligomers may be employed under less stringent conditions for identification of closely related DNAs or RNAs.

Other means of producing specific hybridization probes for hedg include the cloning of nucleic acid sequences encoding HEDG or HEDG derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerase as T7 or SP6 RNA polymerase and the appropriate reporter molecules.

It is possible to produce a DNA sequence, or portions thereof, entirely by synthetic chemistry. After synthesis, the nucleic acid sequence can be inserted into any of the many available DNA vectors and their respective host cells using techniques which are well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into the nucleotide sequence. Alternately, a portion of sequence in which a mutation is desired can be synthesized and recombined with longer portion of an existing genomic or recombinant sequence.

The nucleotide sequence for hedg can be used in an assay to detect inflammation or disease associated with abnormal levels of HEDG expression. The cDNA can be labeled by methods known in the art, added to a fluid, cell or tissue sample from a patient, and incubated under hybridizing



conditions. After an incubation period, the sample is washed with a compatible fluid which optionally contains a reporter molecule. After the compatible fluid is rinsed off, the reporter molecule is quantitated and compared with a standard as previously defined. If kinase expression is significantly different from standard expression, the assay indicates inflammation or disease.

The nucleotide sequence for *hedg* can be used to construct hybridization probes for mapping the native gene. The gene may be mapped to a particular chromosome or to a specific region of a chromosome using well known mapping techniques. These techniques include *in situ* hybridization of chromosomal spreads (Verma et al (1988) Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York City), flow-sorted chromosomal preparations, or artificial chromosome constructions such as yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions or single chromosome cDNA libraries.

*In situ* hybridization of chromosomal preparations and physical mapping techniques such as linkage analysis using established chromosomal markers are invaluable in extending genetic maps. Examples of genetic map data can be found in the yearly genome issue of Science (eg 1994, 265:1981f). Often locating a gene on the chromosome of another mammalian species may reveal associated markers which can be used to help identify the analogous human chromosome.

New nucleotide sequences can be assigned to chromosomal subregions by physical mapping. The mapping of new genes or nucleotide sequences provide useful landmarks for investigators searching for disease genes using positional cloning or other gene discovery techniques. Once a disease or syndrome, such as ataxia telangiectasia (AT), has been crudely localized by genetic linkage to a particular genomic region, for example, AT to 11q22-23 (Gatti et al (1988) Nature 336:577-580), any sequences mapping to that area may represent or reveal genes for further investigation. The nucleotide sequence of the subject invention may also be used to detect differences in gene sequence between normal and carrier or affected individuals.

Nucleotide sequences encoding *hedg* may be used to produce a purified oligo- or polypeptide using well known methods of recombinant DNA technology. Goeddel (1990, Gene Expression Technology, Methods and Enzymology, Vol 185, Academic Press, San Diego CA) is one among many publications which teach expression of an isolated nucleotide sequence. The oligopeptide may be expressed in a variety of host cells, either prokaryotic or eukaryotic. Host cells may be from the same species from which the nucleotide sequence was derived or from a different species. Advantages of producing an oligonucleotide by recombinant DNA technology

include obtaining adequate amounts of the protein for purification and the availability of simplified purification procedures.

Cells transformed with DNA encoding HEDG may be cultured under conditions suitable for the expression of T7Gs, their extracellular, transmembrane or intracellular domains and recovery of such peptides from cell culture. HEDG (or any of its domains) produced by a recombinant cell may be secreted or may be contained intracellularly, depending on the particular genetic construction used. In general, it is more convenient to prepare recombinant proteins in secreted form. Purification steps vary with the production process and the particular protein produced. Often an oligopeptide can be produced from a chimeric nucleotide sequence. This is accomplished by ligating the nucleotides from hedg or a desired portion of the polypeptide to a nucleic acid sequence encoding a polypeptide domain which will facilitate protein purification (Kroll DJ et al (1993) DNA Cell Biol 12:441-53).

In addition to recombinant production, fragments of HEDG may be produced by direct peptide synthesis using solid-phase techniques (eg Stewart et al (1969) Solid-Phase Peptide Synthesis, WH Freeman Co, San Francisco CA; Merrifield J (1963) J Am Chem Soc 85:2149-2154. Automated synthesis may be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Foster City, CA) in accordance with the instructions provided by the manufacturer. Additionally, a particular portion of HEDG may be mutated during direct synthesis and combined with other parts of the peptide using chemical methods.

HEDG for antibody induction does not require biological activity; however, the protein must be antigenic. Peptides used to induce specific antibodies may have an aa sequence consisting of at least five aa, preferably at least 10 aa. They should mimic a portion of the aa sequence of the protein and may contain the entire aa sequence of a small naturally occurring molecule such as HEDG. An antigenic portion of HEDG may be fused to another protein such as keyhole limpet hemocyanin, and the chimeric molecule used for antibody production.

Antibodies specific for HEDG may be produced by inoculation of an appropriate animal with the polypeptide or an antigenic fragment. An antibody is specific for HEDG if it is produced against an epitope of the polypeptide and binds to at least part of the natural or recombinant protein. Antibody production includes not only the stimulation of an immune response by injection into animals, but also analogous processes such as the production of synthetic antibodies, the screening of recombinant immunoglobulin libraries for specific-binding molecules (eg Orlandi R et al (1989) PNAS 86:3833-3837, or Huse WD et al (1989) Science 256:1275-1281) or the *in vitro* stimulation of lymphocyte populations. Current technology (Winter G and Milstein C (1991) Nature 349:293-299) provides for a number of highly specific binding reagents based on the principles of antibody formation. These techniques

may be adapted to produce molecules which specifically bind HEDGs.

An additional embodiment of the subject invention is the use of HEDG specific antibodies, inhibitors, receptors or their analogs as bioactive agents to treat inflammation or disease including, but not limited to viral, bacterial or fungal infections; allergic responses; mechanical injury associated with trauma; hereditary diseases; lymphoma or carcinoma; or other conditions which activate the genes of lymphoid tissues.

Bioactive compositions comprising agonists, antagonists, receptors or inhibitors of HEDG may be administered in a suitable therapeutic dose determined by any of several methodologies including clinical studies on mammalian species to determine maximal tolerable dose and on normal human subjects to determine safe dose. Additionally, the bioactive agent may be complexed with a variety of well established compounds or compositions which enhance stability or pharmacological properties such as half-life. It is contemplated that the therapeutic, bioactive composition may be delivered by intravenous infusion into the bloodstream or any other effective means which could be used for treating problems involving excessive lymphocyte and leukocyte trafficking.

Rheumatoid arthritis is currently evaluated on the basis of swelling, response to NSAIDs, x-rays, etc. HEDG is most likely expressed on the surface of the fibroblasts, T and B lymphocytes, monocyte/macrophages, or mast cells which comprise the cells of the inflamed synovium. Once adequate standards are established, an assay for the abnormal expression of HEDG is a viable diagnostic tool for assessing the extent that RA has progressed. The expression of HEDG in a sustained inflammatory response makes it a valuable therapeutic target for screening drug libraries. Inhibitors of HEDG are useful for controlling signal transduction and signaling cascades in cells of the rheumatoid synovium.

The examples below are provided to illustrate the subject invention. These examples are provided by way of illustration and are not included for the purpose of limiting the invention.

#### INDUSTRIAL APPLICABILITY

##### I Isolation of mRNA and Construction of the cDNA Library

The hedg sequence of this application was first identified in Incyte Clone No. 80853 among the sequences comprising the rheumatoid synovium library. Rheumatoid synovial tissue was obtained from the hip joint removed from a 68 year old female with erosive, nodular rheumatoid arthritis. The tissue was frozen, ground to powder in a mortar and pestle, and lysed immediately in buffer containing guanidinium isothiocyanate. Lysis was followed by several phenol-chloroform extractions and ethanol precipitations. Poly-A+ mRNA was isolated using biotinylated oligo d(T) and streptavidin coupled to paramagnetic particles (Poly(A) Tract Isolation System, Promega, Madison WI).

Using this Poly-A+ mRNA, a custom cDNA library was constructed by Stratagene (La Jolla CA). Synthesis of cDNA was primed with oligo d(T), and adapter oligonucleotides were ligated onto the cDNA molecules enabling them to be inserted into the Uni-ZAP™ vector system (Stratagene). Alternative unidirectional vectors might include, but are not limited to, pcDNA1 (Invitrogen, San Diego CA) and pSHlox-1 (Novagen, Madison WI).

## **I I Isolation of cDNA Clones**

The phagemid forms of individual cDNA clones were obtained by the in vivo excision process, in which the host bacterial strain was co-infected with both the library phage and an f1 helper phage. Polypeptides or enzymes derived from both the library-containing phage and the helper phage nicked the DNA, initiated new DNA synthesis from defined sequences on the target DNA, and created a smaller, single stranded circular phagemid DNA molecule that included all DNA sequences of the pBluescript phagemid and the cDNA insert. The phagemid DNA was released from the cells, purified, and used to reinfect fresh host cells (SOLR™, Stratagene) where double-stranded DNA was produced.

DNA was purified using the QIAWELL-8 Plasmid Purification System (QIAGEN Inc, Chatsworth CA) an anion-exchange resin system with EMPORE™ membrane technology (3M, Minneapolis MN). The DNA was eluted from the purification resin and prepared for DNA sequencing and other analytical manipulations.

## **III Sequencing of cDNA Clones**

The cDNA inserts from random isolates of the rheumatoid synovium library were sequenced in part. Methods for DNA sequencing are well known in the art. Conventional enzymatic methods employed DNA polymerase Klenow fragment, SEQUENASE® (US Biochemical Corp, Cleveland OH) or Taq polymerase to extend DNA chains from an oligonucleotide primer annealed to the DNA template of interest. Methods have been developed for the use of both single- and double-stranded templates. The chain termination reaction products were electrophoresed on urea-acrylamide gels and detected either by autoradiography (for radionuclide-labeled precursors) or by fluorescence (for fluorescent-labeled precursors). Recent improvements in mechanized reaction preparation, sequencing and analysis using the fluorescent detection method have permitted expansion in the number of sequences that are determined per day using machines such as the Catalyst 800 and the Applied Biosystems 377 or 373 DNA sequencers.

## **V Homology Searching of cDNA Clones and Deduced Proteins**

Each sequence so obtained was compared to sequences in GenBank using a search algorithm developed by Applied Biosystems and incorporated into the INHERIT™ 670 Sequence Analysis System. In this algorithm, Pattern Specification Language (developed by TRW Inc, Los

Angeles CA) was used to determine regions of homology. The three parameters that determine how the sequence comparisons run were window size, window offset, and error tolerance. Using a combination of these three parameters, the DNA database was searched for sequences containing regions of homology to the query sequence, and the appropriate sequences were scored with an initial value. Subsequently, these homologous regions were examined using dot matrix homology plots to distinguish regions of homology from chance matches. Smith-Waterman alignments were used to display the results of the homology search.

Peptide and protein sequence homologies were ascertained using the INHERIT™ 670 Sequence Analysis System in a way similar to that used in DNA sequence homologies. Pattern Specification Language and parameter windows were used to search protein databases for sequences containing regions of homology which were scored with an initial value. Dot-matrix homology plots were examined to distinguish regions of significant homology from chance matches.

Alternatively, BLAST, which stands for Basic Local Alignment Search Tool, is used to search for local sequence alignments (Altschul SF (1993) J Mol Evol 36:290-300; Altschul, SF et al (1990) J Mol Biol 215:403-10). BLAST produces alignments of both nucleotide and aa sequences to determine sequence similarity. Because of the local nature of the alignments, BLAST is especially useful in determining exact matches or in identifying homologs. Whereas it is ideal for matches which do not contain gaps, it is inappropriate for performing motif-style searching. The fundamental unit of BLAST algorithm output is the High-scoring Segment Pair (HSP).

An HSP consists of two sequence fragments of arbitrary but equal lengths whose alignment is locally maximal and for which the alignment score meets or exceeds a threshold or cutoff score set by the user. The BLAST approach is to look for HSPs between a query sequence and a database sequence, to evaluate the statistical significance of any matches found, and to report only those matches which satisfy the user-selected threshold of significance. The parameter E establishes the statistically significant threshold for reporting database sequence matches. E is interpreted as the upper bound of the expected frequency of chance occurrence of an HSP (or set of HSPs) within the context of the entire database search. Any database sequence whose match satisfies E is reported in the program output.

#### **V Identification, Full Length Cloning, Sequencing and Translation**

Analysis of INHERIT™ results from randomly picked and sequenced portions of clones from the rheumatoid synovium library identified Incyte 80853 as a homolog of sheep EDG-2 receptor. The partial sequence displayed 92.6% identity with nucleotide sequence of accession U18405 in GenBank (Masana MI et al, supra). The cDNA insert comprising Incyte 80853 was

fully sequenced and used as the basis for cloning the full length cDNA.

The cDNA was extended to full length using a modified XL-PCR (Perkin Elmer) procedure as disclosed in Patent Application Serial No 08/487,112 filed 7 June 1995, and the rheumatoid synovium cDNA library as a template. Primers were designed based on known sequence; one primer was synthesized to initiate extension in the antisense direction (XLR = TCATCTTGATCCCCATCCCTTCTG) and the other to extend sequence in the sense direction (XLF = AGTCTCCGAGTATTGGGTCCTGTG). The primers allowed the sequence to be extended "outward" generating amplicons containing new, unknown nucleotide sequence for the gene of interest. The primers were designed using Oligo 4.0 (National Biosciences Inc, Plymouth MN) to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68°-72° C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations were avoided.

By following the instructions for the XL-PCR kit and thoroughly mixing the enzyme and reaction mix, high fidelity amplification is obtained. Beginning with 25 pMol of each primer and the recommended concentrations of all other components of the kit, PCR was performed using the Peltier Thermal Cycler (PTC200; MJ Research, Watertown MA) and the following parameters:

Step 1	94° C for 60 sec (initial denaturation)
Step 2	94° C for 15 sec
Step 3	65° C for 1 min
Step 4	68° C for 7 min
Step 5	Repeat step 2-4 for 15 additional cycles
Step 6	94° C for 15 sec
Step 7	65° C for 1 min
Step 8	68° C for 7 min + 15 sec/cycle
Step 9	Repeat step 6-8 for 11 additional cycles
Step 10	72° C for 8 min
Step 11	4° C (and holding)

At the end of 28 cycles, 50 µl of the reaction mix was removed; and the remaining reaction mix was run for an additional 10 cycles as outlined below:

Step 1	94° C for 15 sec
Step 2	65° C for 1 min
Step 3	68° C for (10 min + 15 sec)/cycle
Step 4	Repeat step 1-3 for 9 additional cycles
Step 5	72° C for 10 min

A 5-10 µl aliquot of the reaction mixture was analyzed by electrophoresis on a low concentration (about 0.6-0.8%) agarose mini-gel to determine which reactions were successful in extending the sequence. Although all extensions potentially contain a full length gene, some of the largest products or bands were selected and cut out of the gel. Further purification involved using a commercial gel extraction method such as QIAQuick™ (QIAGEN

Inc). After recovery of the DNA, Klenow enzyme was used to trim single-stranded, nucleotide overhangs creating blunt ends which facilitated religation and cloning.

After ethanol precipitation, the products were redissolved in 13  $\mu$ l of ligation buffer. Then, 1  $\mu$ l T4-DNA ligase (15 units) and 1  $\mu$ l T4 polynucleotide kinase were added, and the mixture was incubated at room temperature for 2-3 hours or overnight at 16° C. Competent *E. coli* cells (in 40  $\mu$ l of appropriate media) were transformed with 3  $\mu$ l of ligation mixture and cultured in 80  $\mu$ l of SOC medium (Sambrook J et al, supra). After incubation for one hour at 37° C, the whole transformation mixture was plated on Luria Bertani (LB)-agar (Sambrook J et al, supra) containing carbenicillin at 25 mg/L (2xCarb). The following day, 12 colonies were randomly picked from each plate and cultured in 150  $\mu$ l of liquid LB/2xCarb medium placed in an individual well of an appropriate, commercially-available, sterile 96-well microtiter plate. The following day, 5  $\mu$ l of each overnight culture was transferred into a non-sterile 96-well plate and after dilution 1:10 with water, 5  $\mu$ l of each sample was transferred into a PCR array.

For PCR amplification, 15  $\mu$ l of concentrated PCR reaction mix (1.33X) containing 0.75 units of Taq polymerase, a vector primer and one or both of the gene specific primers used for the extension reaction were added to each well. Amplification was performed using the following conditions:

Step 1	94° C for 60 sec
Step 2	94° C for 20 sec
Step 3	55° C for 30 sec
Step 4	72° C for 90 sec
Step 5	Repeat steps 2-4 for an additional 29 cycles
Step 6	72° C for 180 sec
Step 7	4° C (and holding)

Aliquots of the PCR reactions were run on agarose gels together with molecular weight markers. The sizes of the PCR products were compared to the original partial cDNAs, and appropriate clones were selected, ligated into plasmid and sequenced.

The nucleotide and aa sequences for human HEDG are shown in Figure 1. The coding region of hedg begins at nucleotide 309 and ends at nucleotide 1403 of SEQ ID NO:1. When the three possible translations of HEDG were searched against protein databases such as SwissProt and PIR, no exact matches were found. Figure 2 shows the comparison between the amino acid sequences of HEDG, sheep EDG-2 (U18405) and human EDG-1 (GI 119130).

#### VI Antisense analysis

Knowledge of the correct, complete cDNA sequence of HEDG enables its use as a tool for antisense technology in the investigation of gene function. Oligonucleotides, cDNA or genomic fragments comprising the antisense strand of hedg are used either *in vitro* or *in vivo* to inhibit expression of the mRNA. Such technology is now well known in the art, and antisense molecules

can be designed at various locations along the nucleotide sequences. By treatment of cells or whole test animals with such antisense sequences, the gene of interest is effectively turned off. Frequently, the function of the gene is ascertained by observing behavior at the intracellular, cellular, tissue or organismal level (eg, lethality, loss of differentiated function, changes in morphology, etc).

In addition to using sequences constructed to interrupt transcription of a particular open reading frame, modifications of gene expression is obtained by designing antisense sequences to intron regions, promoter/enhancer elements, or even to trans-acting regulatory genes. Similarly, inhibition is achieved using Hogeboom base-pairing methodology, also known as "triple helix" base pairing.

## VII Expression of HEDG

Expression of *hedg* is accomplished by subcloning the cDNAs into appropriate expression vectors and transfecting the vectors into analogous expression hosts. In this particular case, the cloning vector previously used for the generation of the cDNA library also provides for direct expression of *hedg* sequences in *E. coli*. Upstream of the cloning site, this vector contains a promoter for  $\beta$ -galactosidase, followed by sequence containing the amino-terminal Met and the subsequent 7 residues of  $\beta$ -galactosidase. Immediately following these eight residues is an engineered bacteriophage promoter useful for artificial priming and transcription and for providing a number of unique endonuclease restriction sites for cloning.

Induction of the isolated, transfected bacterial strain with IPTG using standard methods produces a fusion protein corresponding to the first seven residues of  $\beta$ -galactosidase, about 15 residues of "linker", and the peptide encoded within the cDNA. Since cDNA clone inserts are generated by an essentially random process, there is one chance in three that the included cDNA will lie in the correct frame for proper translation. If the cDNA is not in the proper reading frame, it is obtained by deletion or insertion of the appropriate number of bases using well known methods including *in vitro* mutagenesis, digestion with exonuclease III or mung bean nuclease, or the inclusion of an oligonucleotide linker of appropriate length.

The *hedg* cDNA is shuttled into other vectors known to be useful for expression of protein in specific hosts. Oligonucleotide primers containing cloning sites as well as a segment of DNA (about 25 bases) sufficient to hybridize to stretches at both ends of the target cDNA is synthesized chemically by standard methods. These primers are then used to amplify the desired gene segment by PCR. The resulting gene segment is digested with appropriate restriction enzymes under standard conditions and isolated by gel electrophoresis. Alternately, similar gene segments are produced by digestion of the cDNA with appropriate restriction enzymes. Using appropriate primers, segments of coding sequence from more than one gene are



ligated together and cloned in appropriate vectors. It is possible to optimize expression by construction of such chimeric sequences.

Suitable expression hosts for such chimeric molecules include, but are not limited to, mammalian cells such as Chinese Hamster Ovary (CHO) and human 293 cells, insect cells such as Sf9 cells, yeast cells such as *Saccharomyces cerevisiae*, and bacteria such as *E. coli*. For each of these cell systems, a useful expression vector also includes an origin of replication to allow propagation in bacteria and a selectable marker such as the  $\beta$ -lactamase antibiotic resistance gene to allow plasmid selection in bacteria. In addition, the vector may include a second selectable marker such as the neomycin phosphotransferase gene to allow selection in transfected eukaryotic host cells. Vectors for use in eukaryotic expression hosts require RNA processing elements such as 3' polyadenylation sequences if such are not part of the cDNA of interest.

Additionally, the vector contains promoters or enhancers which increase gene expression. Such promoters are host specific and include MMTV, SV40, and metallothionein promoters for CHO cells; trp, lac, tac and T7 promoters for bacterial hosts; and alpha factor, alcohol oxidase and PGH promoters for yeast. Transcription enhancers, such as the rous sarcoma virus enhancer, are used in mammalian host cells. Once homogeneous cultures of recombinant cells are obtained through standard culture methods, large quantities of recombinantly produced HEDG are recovered from the conditioned medium and analyzed using chromatographic methods known in the art.

#### VIII Isolation of Recombinant HEDG

HEDG is expressed as a chimeric protein with one or more additional polypeptide domains added to facilitate protein purification. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp, Seattle WA). The inclusion of a cleavable linker sequence such as Factor XA or enterokinase (Invitrogen) between the purification domain and the HEDG sequence is useful to facilitate expression of HEDG.

#### IX Testing of Chimeric T7Gs

Functional chimeric T7Gs are constructed by combining the extracellular receptive sequences of a new isoform with the transmembrane and intracellular segments of a known isoform for test purposes. This concept was demonstrated by Kobilka et al (1988, Science 240:1310-1316) who created a series of chimeric  $\alpha$ 2- $\beta$ 2 adrenergic receptors (AR) by inserting progressively greater amounts of  $\alpha$ 2-AR transmembrane sequence into  $\beta$ 2-AR. The

binding activity of known agonists changed as the molecule shifted from having more  $\alpha 2$  than  $\beta 2$  conformation, and intermediate constructs demonstrated mixed specificity. The specificity for binding antagonists, however, correlated with the source of the domain VII. The importance of T7G domain VII for ligand recognition was also found in chimeras utilizing two yeast  $\alpha$ -factor  
5 receptors and is significant because the yeast receptors are classified as miscellaneous receptors. Thus, functional role of specific domains appears to be preserved throughout the T7G family regardless of category .

In parallel fashion, internal segments or cytoplasmic domains from a particular isoform are exchanged with the analogous domains of a known T7G and used to identify the  
10 structural determinants responsible for coupling the receptors to trimeric G-proteins (Dohlman et al (1991) Annu Rev Biochem 60:653-88). A chimeric receptor in which domains V, VI, and the intracellular connecting loop from  $\beta 2$ -AR were substituted into  $\alpha 2$ -AR was shown to bind ligands with  $\alpha 2$ -AR specificity, but to stimulate adenylate cyclase in the manner of  $\beta 2$ -AR. This demonstrates that for adrenergic-type receptors, G-protein  
15 recognition is present in domains V and VI and their connecting loop. The opposite situation was predicted and observed for a chimera in which the V->VI loop from  $\alpha 1$ -AR replaced the corresponding domain on  $\beta 2$ -AR and the resulting receptor bound ligands with  $\beta 2$ -AR specificity and activated G-protein-mediated phosphatidylinositol turnover in the  $\alpha 1$ -AR manner. Finally, chimeras constructed from muscarinic receptors also demonstrated that V-  
20 >VI loop is the major determinant for specificity of G-protein activity (Bolander FF, supra).

Chimeric or modified T7Gs containing substitutions in the extracellular and transmembrane regions have shown that these portions of the receptor determine ligand binding specificity. For example, two Ser residues conserved in domain V of all adrenergic and D catecholamine T7G receptors are necessary for potent agonist activity. These serines are  
25 believed to form hydrogen bonds with the catechol moiety of the agonists within the T7G binding site. Similarly, an Asp residue present in domain III of all T7Gs which bind biogenic amines is believed to form an ion pair with the ligand amine group in the T7G binding site.

Functional, cloned T7Gs are expressed in heterologous expression systems and their biological activity assessed (eg Marullo et al (1988) Proc Natl Acad Sci 85:7551-55; King et al (1990) Science 250:121-23). One heterologous system introduces genes for a mammalian  
30 T7G and a mammalian G-protein into yeast cells. The T7G is shown to have appropriate ligand specificity and affinity and trigger appropriate biological activation--growth arrest and morphological changes--of the yeast cells.

An alternate procedure for testing chimeric receptors is based on the procedure  
35 utilizing the  $P_{2U}$  purinergic receptor ( $P_{2U}$ ) as published by Erb et al (1993, Proc Natl Acad

Sci 90:10449-53). Function is easily tested in cultured K562 human leukemia cells because these cells lack  $P_{2U}$  receptors. K562 cells are transfected with expression vectors containing either normal or chimeric  $P_{2U}$  and loaded with fura-a, fluorescent probe for  $Ca^{++}$ . Activation of properly assembled and functional  $P_{2U}$  receptors with extracellular UTP or ATP mobilizes intracellular  $Ca^{++}$  which reacts with fura-a and is measured spectrofluorometrically.

As with the T7G receptors above, chimeric genes are created by combining sequences for extracellular receptive segments of any newly discovered T7G polypeptide with the nucleotides for the transmembrane and intracellular segments of the known  $P_{2U}$  molecule.

Bathing the transfected K562 cells in microwells containing appropriate ligands triggers binding and fluorescent activity defining effectors of the T7G molecule. Once ligand and function are established, the  $P_{2U}$  system is useful for defining antagonists or inhibitors which block binding and prevent such fluorescent reactions.

#### **X Production of HEDG Specific Antibodies**

Two approaches are utilized to raise antibodies to HEDG, and each approach is useful for generating either polyclonal or monoclonal antibodies. In one approach, denatured protein from reverse phase HPLC separation is obtained in quantities up to 75 mg. This denatured protein is used to immunize mice or rabbits using standard protocols; about 100 micrograms are adequate for immunization of a mouse, while up to 1 mg might be used to immunize a rabbit. For identifying mouse hybridomas, the denatured protein is radioiodinated and used to screen potential murine B-cell hybridomas for those which produce antibody. This procedure requires only small quantities of protein, such that 20 mg is sufficient for labeling and screening of several thousand clones.

In the second approach, the amino acid sequence of an appropriate HEDG domain, as deduced from translation of the cDNA, is analyzed to determine regions of high antigenicity. Oligopeptides comprising appropriate hydrophilic regions, as illustrated in Figure 3, are synthesized and used in suitable immunization protocols to raise antibodies. Analysis to select appropriate epitopes is described by Ausubel FM et al (supra). The optimal amino acid sequences for immunization are usually at the C-terminus, the N-terminus and those intervening, hydrophilic regions of the polypeptide which are likely to be exposed to the external environment when the protein is in its natural conformation.

Typically, selected peptides, about 15 residues in length, are synthesized using an Applied Biosystems Peptide Synthesizer Model 431A using fmoc-chemistry and coupled to keyhole limpet hemocyanin (KLH; Sigma, St Louis MO) by reaction with M-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS; Ausubel FM et al, supra). If necessary, a cysteine is

introduced at the N-terminus of the peptide to permit coupling to KLH. Rabbits are immunized with the peptide-KLH complex in complete Freund's adjuvant. The resulting antisera are tested for antipeptide activity by binding the peptide to plastic, blocking with 1% bovine serum albumin, reacting with antisera, washing and reacting with labeled (radioactive or fluorescent), affinity purified, specific goat anti-rabbit IgG.

Hybridomas are prepared and screened using standard techniques. Hybridomas of interest are detected by screening with labeled HEDG to identify those fusions producing the monoclonal antibody with the desired specificity. In a typical protocol, wells of plates (FAST; Becton-Dickinson, Palo Alto CA) are coated during incubation with affinity purified, specific rabbit anti-mouse (or suitable antispecies Ig) antibodies at 10 mg/ml. The coated wells are blocked with 1% BSA, washed and incubated with supernatants from hybridomas. After washing the wells are incubated with labeled HEDG at 1 mg/ml. Supernatants with specific antibodies bind more labeled HEDG than is detectable in the background. Then clones producing specific antibodies are expanded and subjected to two cycles of cloning at limiting dilution. Cloned hybridomas are injected into pristane-treated mice to produce ascites, and monoclonal antibody is purified from mouse ascitic fluid by affinity chromatography on Protein A. Monoclonal antibodies with affinities of at least  $10^8 \text{ M}^{-1}$ , preferably  $10^9$  to  $10^{10}$  or stronger, are typically made by standard procedures as described in Harlow and Lane (1988) Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY; and in Goding (1986) Monoclonal Antibodies: Principles and Practice, Academic Press, New York City, both incorporated herein by reference.

#### **XI Diagnostic Test Using HEDG Specific Antibodies**

Particular HEDG antibodies are useful for investigating signal transduction and the diagnosis of infectious or hereditary conditions which are characterized by differences in the amount or distribution of HEDG or downstream products of an active signaling cascade. Since HEDG was found in a human rheumatoid library, it appears to be upregulated in cell types mainly involved in immune protection or defense.

Diagnostic tests for HEDG include methods utilizing antibody and a label to detect HEDG in human body fluids, membranes, cells, tissues or extracts of such. The polypeptides and antibodies of the present invention are used with or without modification. Frequently, the polypeptides and antibodies are labeled by joining them, either covalently or noncovalently, with a substance which provides for a detectable signal. A wide variety of labels and conjugation techniques are known and have been reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent agents, chemiluminescent agents, chromogenic agents, magnetic particles and the

like. Patents teaching the use of such labels include US Patent Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241. Also, recombinant immunoglobulins may be produced as shown in US Patent No. 4,816,567, incorporated herein by reference.

5 A variety of protocols for measuring soluble or membrane-bound HEDG, using either polyclonal or monoclonal antibodies specific for the protein, are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS). A two-site monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on HEDG is preferred, but a  
10 competitive binding assay may be employed. These assays are described, among other places, in Maddox, DE et al (1983, J Exp Med 158:1211f).

## **XII Purification of Native HEDG Using Specific Antibodies**

Native or recombinant HEDG is purified by immunoaffinity chromatography using antibodies specific for HEDG. In general, an immunoaffinity column is constructed by  
15 covalently coupling the anti-TRH antibody to an activated chromatographic resin.

Polyclonal immunoglobulins are prepared from immune sera either by precipitation with ammonium sulfate or by purification on immobilized Protein A (Pharmacia LKB Biotechnology, Piscataway NJ). Likewise, monoclonal antibodies are prepared from mouse ascites fluid by ammonium sulfate precipitation or chromatography on immobilized Protein A.  
20 Partially purified immunoglobulin is covalently attached to a chromatographic resin such as CnBr-activated Sepharose (Pharmacia LKB Biotechnology). The antibody is coupled to the resin, the resin is blocked, and the derivative resin is washed according to the manufacturer's instructions.

Such immunoaffinity columns are utilized in the purification of HEDG by preparing a  
25 fraction from cells containing HEDG in a soluble form. This preparation is derived by solubilization of whole cells or of a subcellular fraction obtained via differential centrifugation (with or without addition of detergent) or by other methods well known in the art. Alternatively, soluble HEDG containing a signal sequence is secreted in useful quantity into the medium in which the cells are grown.

30 A soluble HEDG-containing preparation is passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of HEDG (eg, high ionic strength buffers in the presence of detergent). Then, the column is eluted under conditions that disrupt antibody/protein binding (eg, a buffer of pH 2-3 or a high concentration of a chaotrope such as urea or thiocyanate ion), and HEDG is collected.

## **XIII Drug Screening**

35

This invention is particularly useful for screening therapeutic compounds by using HEDG or binding fragments thereof in any of a variety of drug screening techniques. The polypeptide or fragment employed in such a test is either free in solution, affixed to a solid support, borne on a cell surface or located intracellularly. One method of drug screening  
5 utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. Such cells, either in viable or fixed form, are used for standard binding assays. One measures, for example, the formation of complexes between HEDG and the agent being tested. Alternatively, one examines the diminution in  
10 complex formation between HEDG and a receptor caused by the agent being tested.

Thus, the present invention provides methods of screening for drugs or any other agents which affect signal transduction. These methods, well known in the art, comprise contacting such an agent with HEDG polypeptide or a fragment thereof and assaying (i) for the presence of a complex between the agent and the HEDG polypeptide or fragment, or (ii) for the presence of a  
15 complex between the HEDG polypeptide or fragment and the cell. In such competitive binding assays, the HEDG polypeptide or fragment is typically labeled. After suitable incubation, free HEDG polypeptide or fragment is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of the particular agent to bind to HEDG or to interfere with the HEDG and agent complex.

Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to the HEDG polypeptides and is described in detail in European Patent Application 84/03564, published on September 13, 1984, incorporated herein by reference. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test  
20 compounds are reacted with HEDG polypeptide and washed. Bound HEDG polypeptide is then detected by methods well known in the art. Purified HEDG are also coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies are used to capture the peptide and immobilize it on the solid support.

This invention also contemplates the use of competitive drug screening assays in which  
25 neutralizing antibodies capable of binding HEDG specifically compete with a test compound for binding to HEDG polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of any peptide which shares one or more antigenic determinants with HEDG.

#### **XIV Rational Drug Design**

The goal of rational drug design is to produce structural analogs of biologically active  
35 polypeptides of interest or of small molecules with which they interact, agonists, antagonists,

or inhibitors. Any of these examples are used to fashion drugs which are more active or stable forms of the polypeptide or which enhance or interfere with the function of a polypeptide in vivo (eg Hodgson J (1991) Bio/Technology 9:19-21, incorporated herein by reference).

5 In one approach, the three-dimensional structure of a protein of interest, or of a protein-inhibitor complex, is determined by x-ray crystallography, by computer modeling or, most typically, by a combination of the two approaches. Both the shape and charges of the polypeptide must be ascertained to elucidate the structure and to determine active site(s) of the molecule. Less often, useful information regarding the structure of a polypeptide is gained by modeling based on the structure of homologous proteins. In both cases, relevant structural  
10 information is used to design efficient inhibitors. Useful examples of rational drug design includes molecules which have improved activity or stability as shown by Braxton S and Wells JA (1992, Biochemistry 31:7796- 7801) or which act as inhibitors, agonists, or antagonists of native peptides as shown by Athauda SB et al (1993 J Biochem 113:742-46), incorporated herein by reference.

15 It is also possible to isolate a target-specific antibody, selected by functional assay, as described above, and then to solve its crystal structure. This approach, in principle, yields a pharmacore upon which subsequent drug design is based. It is possible to bypass protein crystallography altogether by generating anti-idiotypic antibodies (anti-ids) to a functional, pharmacologically active antibody. As a mirror image of a mirror image, the binding site of the  
20 anti-ids is expected to be an analog of the original receptor. The anti-id is then used to identify and isolate peptides from banks of chemically or biologically produced peptides. The isolated peptides then act as the pharmacore.

By virtue of the present invention, sufficient amount of polypeptide are made available to perform such analytical studies as X-ray crystallography. In addition, knowledge of the  
25 HEDG amino acid sequence provided herein provides guidance to those employing computer modeling techniques in place of or in addition to x-ray crystallography.

#### **XV Identification of Other Members of the Signal Transduction Complex**

The inventive purified HEDG is a research tool for identification, characterization and purification of interacting G or other signal transduction pathway proteins. Radioactive labels  
30 are incorporated into a selected HEDG domain by various methods known in the art and used in vitro to capture interacting molecules. A preferred method involves labeling the primary amino groups in HEDG with <sup>125</sup>I Bolton-Hunter reagent (Bolton, AE and Hunter, WM (1973) Biochem J 133: 529). This reagent has been used to label various molecules without concomitant loss of biological activity (Hebert CA et al (1991) J Biol Chem 266: 18989;  
35 McColl S et al (1993) J Immunol 150:4550-4555).

Labeled HEDG is useful as a reagent for the purification of molecules with which it interacts. In one embodiment of affinity purification, membrane-bound HEDG is covalently coupled to a chromatography column. Cell-free extract derived from synovial cells or putative target cells is passed over the column, and molecules with appropriate affinity bind to HEDG.

5 HEDG-complex is recovered from the column, and the HEDG-binding ligand disassociated and subjected to N-terminal protein sequencing. This aa sequence is then used to identify the captured molecule or to design degenerate oligonucleotide probes for cloning the relevant gene from an appropriate cDNA library.

10 In an alternate method, antibodies are raised against HEDG, specifically monoclonal antibodies. The monoclonal antibodies are screened to identify those which inhibit the binding of labeled HEDG. These monoclonal antibodies are then used therapeutically.

#### **XVI Use and Administration of Antibodies, Inhibitors, or Antagonists**

15 Antibodies, inhibitors, or antagonists of HEDG (or other treatments to limit signal transduction, LST) provide different effects when administered therapeutically. LSTs are formulated in a nontoxic, inert, pharmaceutically acceptable aqueous carrier medium preferably at a pH of about 5 to 8, more preferably 6 to 8, although pH may vary according to the characteristics of the antibody, inhibitor, or antagonist being formulated and the condition to be treated. Characteristics of LSTs include solubility of the molecule, half-life and antigenicity/immunogenicity. These and other characteristics aid in defining an effective

20 carrier. Native human proteins are preferred as LSTs, but organic or synthetic molecules resulting from drug screens are equally effective in particular situations.

LSTs are delivered by known routes of administration including but not limited to topical creams and gels; transmucosal spray and aerosol; transdermal patch and bandage; injectable, intravenous and lavage formulations; and orally administered liquids and pills particularly

25 formulated to resist stomach acid and enzymes. The particular formulation, exact dosage, and route of administration is determined by the attending physician and varies according to each specific situation.

Such determinations are made by considering multiple variables such as the condition to be treated, the LST to be administered, and the pharmacokinetic profile of a particular LST.

30 Additional factors which are taken into account include severity of the disease state, patient's age, weight, gender and diet, time and frequency of LST administration, possible combination with other drugs, reaction sensitivities, and tolerance/response to therapy. Long acting LST formulations might be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular LST.

35 Normal dosage amounts vary from 0.1 to 100,000 micrograms, up to a total dose of



about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature; see US Patent Nos. 4,657,760; 5,206,344; or 5,225,212. Those skilled in the art employ different formulations for different LSTs. Administration to cells such as nerve cells necessitates delivery in a manner different from that to other cells such as vascular endothelial cells.

It is contemplated that abnormal signal transduction, trauma, or diseases which trigger HEDG activity are treatable with LSTs. These conditions or diseases are specifically diagnosed by the tests discussed above, and such testing should be performed in suspected cases of viral, bacterial or fungal infections; allergic responses; mechanical injury associated with trauma; hereditary diseases; lymphoma or carcinoma; or other conditions which activate the genes of lymphoid tissues.

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the above-described modes for carrying out the invention which are obvious to those skilled in the field of molecular biology or related fields are intended to be within the scope of the following claims.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION

- (i) APPLICANT: Coleman, Roger  
Guegler, Karl J.  
Au-Young, Janice  
Bandman, Olga  
Seilhamer, Jeffrey J.
  - (ii) TITLE OF THE INVENTION: A NOVEL HUMAN EDG-2 RECEPTOR HOMOLOG
  - (iii) NUMBER OF SEQUENCES: 6
  - (iv) CORRESPONDENCE ADDRESS:
    - (A) ADDRESSEE: Incyte Pharmaceuticals, Inc.
    - (B) STREET: 3174 Porter Drive
    - (C) CITY: Palo Alto
    - (D) STATE: CA
    - (E) COUNTRY: USA
    - (F) ZIP: 94304
  - (v) COMPUTER READABLE FORM:
    - (A) MEDIUM TYPE: Diskette
    - (B) COMPUTER: IBM Compatible
    - (C) OPERATING SYSTEM: DOS
    - (D) SOFTWARE: FastSEQ Version 1.5
  - (vi) CURRENT APPLICATION DATA:
    - (A) APPLICATION NUMBER: TO BE ASSIGNED
    - (B) FILING DATE: 20-JUN-1996
    - (C) CLASSIFICATION:
  - (vii) PRIOR APPLICATION DATA:
    - (A) APPLICATION NUMBER: 60/000,352
    - (B) FILING DATE: 20-JUN-1995
  - (vii) PRIOR APPLICATION DATA:
    - (A) APPLICATION NUMBER: 08/567,817
    - (B) FILING DATE: 06-DEC-1995
  - (viii) ATTORNEY/AGENT INFORMATION:
    - (A) NAME: Glaister, Debra J.
    - (B) REGISTRATION NUMBER: 33,888
    - (C) REFERENCE/DOCKET NUMBER: PF-0042 PCT
  - (ix) TELECOMMUNICATION INFORMATION:
    - (A) TELEPHONE: 415-855-0555
    - (B) TELEFAX: 415-845-4166
    - (C) TELEX:
- (2) INFORMATION FOR SEQ ID NO:1:
- (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 1875 base pairs
    - (B) TYPE: nucleic acid
    - (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:

(A) LIBRARY: Rheumatoid Synovium

(B) CLONE: 80853

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```

GGCAGGTACG GCCGGATTCC CGGGTCGACC ACGCGTCCGC TCTCAAGGGA ACAGCTCCTG      60
CCCAGGTCTG TGGGTACTCA GCATGGATAT CAGTCTCCCT GTGAGTGATG GGAAAGAACT      120
AGCAGAGGTG GACGCTGTAT TTATGAAGCT CCCCATCCAC CTATCTGAGT ACCTGACTTC      180
TCAGGACTGA CACCTACAGC ATCAGGTACA CAGCTTCTCC TAGCATGACT TCGATCTGAT      240
CACCACACAA GAAAAATTTGT CTCCCGTAGT TCTGGGGCGT GTTACCACC TACAACCACA      300
GAGCTGTCTAT GGCTGCCATC TCTACTTCCA TCCCTGTAAT TTCACAGCCC CAGTTCACAG      360
CCATGAATGA ACCACAGTGC TTCTACAACG AGTCCATTGC CTTCTTTTAT AACCGAAGTG      420
GAAAGCATCT TGGCCACAGAA TGGAACACAG TCAGCAAGCT GGTGATGGGA CTTGGAATCA      480
CTGTTTGTAT CTTTCATCATG TTGGCCAACC TATTGGTCAT GGTGGCAATC TATGTCAACC      540
GCCGCTTCCA TTTTCTTATT TATTACCTAA TGGCTAATCT GGCTGCTGCA GACTTCTTTG      600
CTGGGTGGC CTACTTCTAT CTCATGTTCA ACACAGGACC CAATACTCGG AGACTGACTG      660
TTAGCACATG GCTCCTTCGT CAGGGCCTCA TTGACACCAG CCTGACGGCA TCTGTGGCCA      720
ACTTACTGGC TATTGCAATC GAGAGGCACA TTACGGTTTT CCGCATGCAG CTCCACACAC      780
GGATGAGCAA CCGGCGGGTA GTGGTGGTCA TTGTGGTCAT CTGGACTATG GCCATCGTTA      840
TGGGTGCTAT ACCCAGTGTG GGCTGGAAC GTATCTGTGA TATTGAAAAT TGTTCCAACA      900
TGGCACCCT CTACAGTGAC TCTTACTTAG TCTTCTGGGC CATTTTCAAC TTGGTGACCT      960
TTGTGGTAAT GGTGGTTCTC TATGCTACA TCTTTGGCTA TGTTCGCCAG AGGACTATGA     1020
GAATGTCTCG GCATAGTTCT GGACCCCGGC GGAATCGGGA TACCATGATG AGTCTTCTGA     1080
AGACTGTGGT CATTGTGCTT GGGGGCTTTA TCATCTGCTG GACTCCTGGA TTGGTTTTGT     1140
TACTTCTAGA CGTGTGCTGT CCACAGTGCG ACGTGTGCGC CTATGAGAAA TTCTTCCTTC     1200
TCCTTGCTGA ATTCAACTCT GCCATGAACC CCATCATTTA CTCCTACCGT GACAAAGAAA     1260
TGAGCGCCAC CTTTAGACAG ATCCTCTGCT GCCAGCGCAG TGAGAAACCC ACCGCCCCCA     1320
CAGAAGGCTC AGACCGCTCG GCTTCTCCC TCAACCACAC CATCTTGGCT GGAGTTCACA     1380
GCAATGACCA CTCTGTGGTT TAGAACGGAA ACTGAGATGA GGAACAGCC GTCTCTCTTT     1440
GGAGGATAAA CAAGCCTCCC CCTACCCAAT TGCCAGGGCA AGGTGGGGTG TGAGAGAGGA     1500
GAAAAGTCAA CTCATGTACT TAAACACTAA CCAATGACAG TATTTGTTC TGGACCCAC     1560
AAGACTTGAT ATATATTGAA AATTAGCTTA TGTGACAACC CTCATCTTGA TCCCCATCCC     1620
TTCTGAAAGT AGGAAGTTGG AGCTCTTGCA ATGGAATTCA AGAACAGACT CTGGAGTGTC     1680
CATTAGACT AACTAACTA GACTTTTAAA AGATTTTGTG TGGTTTGGTG CAAGTCAGAA     1740
TAAATTCTGG CTAGTTGAAT CCACAACCTC ATTTATATAC AGGCTTCCCT TTTTATTTT     1800
TAAAGGATAC GTTTCACCTA ATAAACACGT TTATGCCTAA AAAAAAAAAA AAAAAAAAAA     1860
AAAAAAAAAA AAAAC                                     1875

```

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 364 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vii) IMMEDIATE SOURCE:

(A) LIBRARY: Rheumatoid Synovium

(B) CLONE: 80853

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```

Met Ala Ala Ile Ser Thr Ser Ile Pro Val Ile Ser Gln Pro Gln Phe
 1           5           10           15

```

```

Thr Ala Met Asn Glu Pro Gln Cys Phe Tyr Asn Glu Ser Ile Ala Phe
      20      25      30
Phe Tyr Asn Arg Ser Gly Lys His Leu Ala Thr Glu Trp Asn Thr Val
      35      40      45
Ser Lys Leu Val Met Gly Leu Gly Ile Thr Val Cys Ile Phe Ile Met
      50      55      60
Leu Ala Asn Leu Leu Val Met Val Ala Ile Tyr Val Asn Arg Arg Phe
      65      70      75      80
His Phe Pro Ile Tyr Tyr Leu Met Ala Asn Leu Ala Ala Ala Asp Phe
      85      90      95
Phe Ala Gly Leu Ala Tyr Phe Tyr Leu Met Phe Asn Thr Gly Pro Asn
      100      105      110
Thr Arg Arg Leu Thr Val Ser Thr Trp Leu Leu Arg Gln Gly Leu Ile
      115      120      125
Asp Thr Ser Leu Thr Ala Ser Val Ala Asn Leu Leu Ala Ile Ala Ile
      130      135      140
Glu Arg His Ile Thr Val Phe Arg Met Gln Leu His Thr Arg Met Ser
      145      150      155      160
Asn Arg Arg Val Val Val Val Ile Val Val Ile Trp Thr Met Ala Ile
      165      170      175
Val Met Gly Ala Ile Pro Ser Val Gly Trp Asn Cys Ile Cys Asp Ile
      180      185      190
Glu Asn Cys Ser Asn Met Ala Pro Leu Tyr Ser Asp Ser Tyr Leu Val
      195      200      205
Phe Trp Ala Ile Phe Asn Leu Val Thr Phe Val Val Met Val Val Leu
      210      215      220
Tyr Ala His Ile Phe Gly Tyr Val Arg Gln Arg Thr Met Arg Met Ser
      225      230      235      240
Arg His Ser Ser Gly Pro Arg Arg Asn Arg Asp Thr Met Met Ser Leu
      245      250      255
Leu Lys Thr Val Val Ile Val Leu Gly Gly Phe Ile Ile Cys Trp Thr
      260      265      270
Pro Gly Leu Val Leu Leu Leu Leu Asp Val Cys Cys Pro Gln Cys Asp
      275      280      285
Val Leu Ala Tyr Glu Lys Phe Phe Leu Leu Leu Ala Glu Phe Asn Ser
      290      295      300
Ala Met Asn Pro Ile Ile Tyr Ser Tyr Arg Asp Lys Glu Met Ser Ala
      305      310      315      320
Thr Phe Arg Gln Ile Leu Cys Cys Gln Arg Ser Glu Asn Pro Thr Ala
      325      330      335
Pro Thr Glu Gly Ser Asp Arg Ser Ala Ser Ser Leu Asn His Thr Ile
      340      345      350
Leu Ala Gly Val His Ser Asn Asp His Ser Val Val
      355      360

```

## (2) INFORMATION FOR SEQ ID NO:3:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 393 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (vii) IMMEDIATE SOURCE:

- (A) LIBRARY: GenBank
- (B) CLONE:U18405

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```

Met Ala Ala Ala Ser Thr Ser Ser Pro Val Val Ser Gln Pro Gln Phe
1      5      10      15
Thr Ala Met Asn Glu Pro Gln Cys Phe Tyr Asn Glu Ser Ile Ala Phe
20      25      30
Phe Tyr Asn Arg Ser Gly Lys Tyr Leu Ala Thr Glu Trp Asn Thr Val
35      40      45
Ser Lys Leu Val Met Gly Leu Gly Ile Thr Val Cys Ile Phe Ile Met
50      55      60
Leu Ala Asn Leu Leu Val Met Val Ala Ile Tyr Val Asn Arg Arg Phe
65      70      75      80
His Phe Pro Ile Tyr Tyr Leu Met Ala Asn Leu Ala Ala Ala Asp Phe
85      90      95
Phe Ala Gly Leu Ala Tyr Phe Tyr Leu Met Phe Asn Thr Gly Pro Asn
100     105     110
Thr Arg Arg Leu Thr Val Ser Thr Trp Leu Leu Arg Gln Gly Leu Ile
115     120     125
Asp Thr Thr Val Thr Ala Ser Val Ala Asn Leu Leu Ala Ile Ala Ile
130     135     140
Glu Arg His Ile Thr Val Phe Arg Met Gln Leu His Thr Arg Met Ser
145     150     155     160
Asn Arg Arg Val Val Val Val Ile Val Val Ile Trp Thr Met Ala Ile
165     170     175
Val Met Gly Ala Ile Pro Ser Val Gly Trp Asn Cys Ile Cys Asp Ile
180     185     190
Glu Asn Cys Ser Asn Met Ala Pro Leu Tyr Ser Asp Ser Tyr Leu Val
195     200     205
Phe Trp Ala Ile Phe Asn Leu Val Thr Phe Val Val Met Val Val Leu
210     215     220
Tyr Ala His Ile Phe Gly Tyr Val Arg Gln Arg Thr Met Arg Met Ser
225     230     235     240
Arg His Ser Ser Gly Pro Arg Arg Asn Arg Asp Thr Met Met Ser Leu
245     250     255
Leu Lys Thr Val Val Ile Val Leu Gly Ala Phe Ile Ile Cys Trp Thr
260     265     270
Pro Gly Leu Val Leu Leu Leu Leu Asp Val Cys Cys Pro Gln Cys Asp
275     280     285
Val Leu Ala Tyr Glu Lys Phe Phe Leu Leu Leu Ala Glu Phe Asn Ser
290     295     300
Ala Met Asn Pro Ile Ile Tyr Ser Tyr Arg Asp Lys Glu Met Ser Ala
305     310     315     320
Thr Phe Arg Gln Ile Leu Cys Cys Gln Arg Ser Glu Asn Thr Ser Gly
325     330     335
Pro Thr Glu Gly Ser Asp Arg Ser Ala Ser Ser Leu Asn His Thr Ile
340     345     350
Leu Ala Gly Val His Ser Asn Asp His Ser Val Phe Arg Lys Glu Thr
355     360     365
Lys Met Arg Gly Gly His His Leu Leu Arg Asp Glu Gln Pro Pro Pro
370     375     380
Pro Glu Arg Pro Gly Gln Gly Arg Val
385     390

```

## (2) INFORMATION FOR SEQ ID NO:4:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 381 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (vii) IMMEDIATE SOURCE:

(A) LIBRARY: GenBank

(B) CLONE: 119130

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```

Met Gly Pro Thr Ser Val Pro Leu Val Lys Ala His Arg Ser Ser Val
 1      5      10      15
Ser Asp Tyr Val Asn Tyr Asp Ile Ile Val Arg His Tyr Asn Tyr Thr
      20      25      30
Gly Lys Leu Asn Ile Ser Ala Asp Lys Glu Asn Ser Ile Lys Leu Thr
      35      40      45
Ser Val Val Phe Ile Leu Ile Cys Cys Phe Ile Ile Leu Glu Asn Ile
      50      55      60
Phe Val Leu Leu Thr Ile Trp Lys Thr Lys Lys Phe His Arg Pro Met
65      70      75      80
Tyr Tyr Phe Ile Gly Asn Leu Ala Leu Ser Asp Leu Leu Ala Gly Val
      85      90      95
Ala Tyr Thr Ala Asn Leu Leu Leu Ser Gly Ala Thr Thr Tyr Lys Leu
      100     105     110
Thr Pro Ala Gln Trp Phe Leu Arg Glu Gly Ser Met Phe Val Ala Leu
      115     120     125
Ser Ala Ser Val Phe Ser Leu Leu Ala Ile Ala Ile Glu Arg Tyr Ile
      130     135     140
Thr Met Leu Lys Met Lys Leu His Asn Gly Ser Asn Asn Phe Arg Leu
145     150     155     160
Phe Leu Leu Ile Ser Ala Cys Trp Val Ile Ser Leu Ile Leu Gly Gly
      165     170     175
Leu Pro Ile Met Gly Trp Asn Cys Ile Ser Ala Leu Ser Ser Cys Ser
      180     185     190
Thr Val Leu Pro Leu Tyr His Lys His Tyr Ile Leu Phe Cys Thr Thr
      195     200     205
Val Phe Thr Leu Leu Leu Leu Ser Ile Val Ile Leu Tyr Cys Arg Ile
      210     215     220
Tyr Ser Leu Val Arg Thr Arg Ser Arg Arg Leu Thr Phe Arg Lys Asn
225     230     235     240
Ile Ser Lys Ala Ser Arg Ser Ser Glu Asn Val Ala Leu Leu Lys Thr
      245     250     255
Val Ile Ile Val Leu Ser Val Phe Ile Ala Cys Trp Ala Pro Leu Phe
      260     265     270
Ile Leu Leu Leu Leu Asp Val Gly Cys Lys Val Lys Thr Cys Asp Ile
      275     280     285
Leu Phe Arg Ala Glu Tyr Phe Leu Val Leu Ala Val Leu Asn Ser Gly
      290     295     300
Thr Asn Pro Ile Ile Tyr Thr Leu Thr Asn Lys Glu Met Arg Arg Ala
305     310     315     320
Phe Ile Arg Ile Met Ser Cys Cys Lys Cys Pro Ser Gly Asp Ser Ala
      325     330     335
Gly Lys Phe Lys Arg Pro Ile Ile Ala Gly Met Glu Phe Ser Arg Ser
      340     345     350
Lys Ser Asp Asn Ser Ser His Pro Gln Lys Asp Glu Gly Asp Asn Pro
      355     360     365
Glu Thr Ile Met Ser Ser Gly Asn Val Asn Ser Ser Ser
      370     375     380

```

## (2) INFORMATION FOR SEQ ID NO:5:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 base pairs

(B) TYPE: nucleic acid

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (vii) IMMEDIATE SOURCE:
- (A) Oligomer R

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

TCATCTTGAT CCCCATCCCT TCTG

24

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 24 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (vii) IMMEDIATE SOURCE:
- (A) Oligomer F

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

AGTCTCCGAG TATTGGGTCC TGTG

24

## CLAIMS

1. A purified polynucleotide comprising a nucleic acid sequence encoding the polypeptide of SEQ ID NO:2, or the complement of said polynucleotide.
2. The polynucleotide of Claim 1 comprising the nucleic acid sequence for (hedg) of SEQ ID NO:1.
3. An antisense molecule comprising the complement of the polynucleotide of Claim 2 or a portion thereof.
4. A pharmaceutical composition comprising the antisense molecule of Claim 3 and a pharmaceutically acceptable excipient.
5. A method of treating a subject with a condition associated with altered hedg expression comprising administering an effective amount of the pharmaceutical composition of Claim 4 to the subject.
6. A diagnostic composition comprising an oligomer of the polynucleotide of Claim 2.
7. A diagnostic test for a condition associated with altered hedg expression comprising the steps of:
  - a) providing a biological sample;
  - b) combining the biological sample and the diagnostic composition of Claim 6;
  - c) allowing hybridization to occur between the biological sample and the diagnostic composition under suitable conditions;
  - d) measuring the amount of hybridization to obtain a sample value; and
  - e) comparing the sample value with standard values to determine whether hedg expression is altered.
8. An expression vector comprising the polynucleotide of Claim 1.
9. A host cell transformed with the expression vector of Claim 8.
10. A method for producing a polypeptide, said method comprising the steps of:
  - a) culturing the host cell of Claim 9 under conditions suitable for the expression of the polypeptide; and
  - b) recovering the polypeptide from the host cell culture.
11. A purified polypeptide (HEDG) comprising the amino acid sequence of SEQ ID NO:2.
12. A diagnostic composition comprising the polypeptide of Claim 11 or a portion thereof.
13. A pharmaceutical composition comprising the polypeptide of Claim 11 and a pharmaceutically acceptable excipient.
14. A method of treating a subject with a condition associated with altered HEDG expression comprising administering an effective amount of the pharmaceutical composition of Claim 13 to the subject.



15. An antibody specific for the purified polypeptide of Claim 11, or portion thereof.

16. A diagnostic composition comprising the antibody of Claim 15.

17. A diagnostic test for a condition associated with altered HEDG expression comprising the steps of:

- 5           a) providing a biological sample;
- b) combining the biological sample and the antibody of Claim 15 under conditions suitable for complex formation;
- c) measuring the amount of complex formation between HEDG and the antibody to obtain a sample amount; and
- 10           d) comparing the amount of complex formation in the sample with standard amounts of complex formation, wherein a variation between the sample amount and standard amounts of complex formation establishes the presence of the condition.

18. A method of screening a plurality of compounds for specific binding affinity with the polypeptide of Claim 11 or any portion thereof comprising the steps of:

- 15           a) providing a plurality of compounds;
- b) combining HEDG with each of a plurality of compounds for a time sufficient to allow binding under suitable conditions; and
- c) detecting binding of HEDG to each of the plurality of compounds, thereby identifying the compounds which specifically bind HEDG.

20           19. A pharmaceutical composition comprising a compound of Claim 18 and a pharmaceutically acceptable excipient.

20. A method of treating a subject with a condition associated with altered HEDG expression comprising administering an effective amount of the pharmaceutical composition of Claim 19 to the subject.

1/3

```

      9      18      27      36      45      54
5' ATG GCT GCC ATC TCT ACT TCC ATC CCT GTA ATT TCA CAG CCC CAG TTC ACA GCC
  M  A  A  I  S  T  S  I  P  V  I  S  Q  P  Q  F  T  A

      63      72      81      90      99      108
ATG AAT GAA CCA CAG TGC TTC TAC AAC GAG TCC ATT GCC TTC TTT TAT AAC CGA
M  N  E  P  Q  C  F  Y  N  E  S  I  A  F  F  Y  N  R

      117      126      135      144      153      162
AGT GGA AAG CAT CTT GCC ACA GAA TGG AAC ACA GTC AGC AAG CTG GTG ATG GGA
S  G  K  H  L  A  T  E  W  N  T  V  S  K  L  V  M  G

      171      180      189      198      207      216
CTT GGA ATC ACT GTT TGT ATC TTC ATC ATG TTG GCC AAC CTA TTG GTC ATG GTG
L  G  I  T  V  C  I  F  I  M  L  A  N  L  L  V  M  V

      225      234      243      252      261      270
GCA ATC TAT GTC AAC CGC CGC TTC CAT TTT CCT ATT TAT TAC CTA ATG GCT AAT
A  I  Y  V  N  R  R  F  H  F  P  I  Y  Y  L  M  A  N

      279      288      297      306      315      324
CTG GCT GCT GCA GAC TTC TTT GCT GGG TTG GCC TAC TTC TAT CTC ATG TTC AAC
L  A  A  A  D  F  F  A  G  L  A  Y  F  Y  L  M  F  N

      333      342      351      360      369      378
ACA GGA CCC AAT ACT CGG AGA CTG ACT GTT AGC ACA TGG CTC CTT CGT CAG GGC
T  G  P  N  T  R  R  L  T  V  S  T  W  L  L  R  Q  G

      387      396      405      414      423      432
CTC ATT GAC ACC AGC CTG ACG GCA TCT GTG GCC AAC TTA CTG GCT ATT GCA ATC
L  I  D  T  S  L  T  A  S  V  A  N  L  L  A  I  A  I

      441      450      459      468      477      486
GAG AGG CAC ATT ACG GTT TTC CGC ATG CAG CTC CAC ACA CGG ATG AGC AAC CGG
E  R  H  I  T  V  F  R  M  Q  L  H  T  R  M  S  N  R

      495      504      513      522      531      540
CGG GTA GTG GTG GTC ATT GTG GTC ATC TGG ACT ATG GCC ATC GTT ATG GGT GCT
R  V  V  V  V  I  V  V  I  W  T  M  A  I  V  M  G  A

      549      558      567      576      585      594
ATA CCC AGT GTG GGC TGG AAC TGT ATC TGT GAT ATT GAA AAT TGT TCC AAC ATG
I  P  S  V  G  W  N  C  I  C  D  I  E  N  C  S  N  M

      603      612      621      630      639      648
GCA CCC CTC TAC AGT GAC TCT TAC TTA GTC TTC TGG GCC ATT TTC AAC TTG GTG
A  P  L  Y  S  D  S  Y  L  V  F  W  A  I  F  N  L  V

      657      666      675      684      693      702
ACC TTT GTG GTA ATG GTG GTT CTC TAT GCT CAC ATC TTT GGC TAT GTT CGC CAG
T  F  V  V  M  V  V  L  Y  A  H  I  F  G  Y  V  R  Q

      711      720      729      738      747      756
AGG ACT ATG AGA ATG TCT CGG CAT AGT TCT GGA CCC CGG CGG AAT CGG GAT ACC
R  T  M  R  M  S  R  H  S  S  G  P  R  R  N  R  D  T

      765      774      783      792      801      810
ATG ATG AGT CTT CTG AAG ACT GTG GTC ATT GTG CTT GGG GGC TTT ATC ATC TGC
M  M  S  L  L  K  T  V  V  I  V  L  G  G  F  I  I  C

      819      828      837      846      855      864
TGG ACT CCT GGA TTG GTT TTG TTA CTT CTA GAC GTG TGC TGT CCA CAG TGC GAC
W  T  P  G  L  V  L  L  L  L  D  V  C  C  P  Q  C  D

```

FIGURE 1A

2/3

873	882	891	900	909	918
GTG CTG GCC TAT GAG AAA TTC TTC CTT CTC CTT GCT GAA TTC AAC TCT GCC ATG					
V L A Y E K F F L L L A E F N S A M					
927	936	945	954	963	972
AAC CCC ATC ATT TAC TCC TAC CGT GAC AAA GAA ATG AGC GCC ACC TTT AGA CAG					
N P I I Y S Y R D K E M S A T F R Q					
981	990	999	1008	1017	1026
ATC CTC TGC TGC CAG CGC AGT GAG AAC CCC ACC GCC CCC ACA GAA GGC TCA GAC					
I L C C Q R S E N P T A P T E G S D					
1035	1044	1053	1062	1071	1080
CGC TCG GCT TCC TCC CTC AAC CAC ACC ATC TTG GCT GGA GTT CAC AGC AAT GAC					
R S A S S L N H T I L A G V H S N D					
1089					
CAC TCT GTG GTT TAG 3'					
H S V V *					

FIGURE 1B

3/3

1 MAAISTSI PVISQPQFTAMNEPQCFYNESI 80853  
 1 MAAASTSS PVVISOPOFTAMNEPOCFYNESI U18405  
 1 MGP--TSVPLVKAHRSSV---SDYVNYDII GI 119130

31 AFFYNRSGK-HLATEWNTVSKLVMGLGITV 80853  
 31 AFFYNRSGK-YLATEWNTVSKLVMGLGITV U18405  
 26 VRHYNYTGKLNISADKENSTIKLTSVVFI LI GI 119130

60 CIFI MLANLLVMVAIYVNRRFHFPIYYLMA 80853  
 60 CIFI MLANLLVMVAIYVNRRFHFPIYYLMA U18405  
 56 CCFIILENIFVLLTIWKTKKFEHRPMYYFIG GI 119130

90 NLAAADFFAGLAYFYLMFNTGPNTRRLTVS 80853  
 90 NLAAADFFAGLAYFYLMFNTGPNTRRLTVS U18405  
 86 NLALSDDLAVAYTANLLLSGATTYKLTTPA GI 119130

120 TWLLRQGLIDTSLTASVANLLAIAIERHIT 80853  
 120 TWLLRQGLIDT TVTASVANLLAIAIERHIT U18405  
 116 QWFLREIGSMFVALSASVFSLLAIAIERVYIT GI 119130

150 VFRMQLHTRMSNRRVVVVIVVIWTMAIVMG 80853  
 150 VFRMQLHTRMSNRRVVVVIVVIWTMAIVMG U18405  
 146 MLKMKLHNGSNNFRLFLLLISACWVISLILG GI 119130

180 AIPSVGWNCICDIENCSNMAPLYSDSYLVF 80853  
 180 AIPSVGWNCICDIENCSNMAPLYSDSYLVF U18405  
 176 GLPIIMGWNCISALSSCSTVLPPLYHKHYILF GI 119130

210 -WAI FNLVTFVVMVLYAHIFGYVRQRTMR 80853  
 210 -WAI FNLVTFVVMVLYAHIFGYVRQRTMR U18405  
 206 CTTVFETLL-LLSIVTILYCRITYSLVRTRSRR GI 119130

239 MSRHSSGPRRNRDTM-MSLLKTVVIVLGGF 80853  
 239 MSRHSSGPRRNRDTM-MSLLKTVVIVLGAFF U18405  
 235 LTFRKNISKASRSSENVALLKTVIIVLSVF GI 119130

268 IICWTPGLVLLLLLDVCCP--QCDVLAYEKF 80853  
 268 IICWTPGLVLLLLLDVCCP--QCDVLAYEKF U18405  
 265 IACWAPLFI LLLLDVGCKVKTCDTILFRAEY GI 119130

296 FLLLAEFNSAMNP I IYSYRDKEMSATFRQI 80853  
 296 FLLLAEFNSAMNP I IYSYRDKEMSATFRQI U18405  
 295 FLVLA VLN SGTNP I IYTLTNKEMRRAFIRI GI 119130

326 LCCORSENPTAPTEGSDRSASSLNHTILAG 80853  
 326 LCCORSENTSGPTEGSDRSASSLNHTILAG U18405  
 325 MSCCKCP-----SGDSAGKFKRPITAG GI 119130

356 VHSNDHSV----- 80853  
 356 VHSNDHSVFRKETKMRGGHLLRDEQPPPP U18405  
 347 ME-----FSR-SKSDNSSHPQKDEGDNPE GI 119130

364 -----V 80853  
 386 ERPGQGRV U18405  
 370 TIMSSGNVNSSS GI 119130

Decoration 'Decoration #1': Box residues that match 80853 exactly.

FIGURE 2



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/12, C07K 14/705, 16/18,</b> <b>C12N 15/11, 5/10, G01N 33/53,</b> <b>A61K 38/17</b>		<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 97/00952</b> <b>(43) International Publication Date:</b> 9 January 1997 (09.01.97)
<b>(21) International Application Number:</b> PCT/US96/10618 <b>(22) International Filing Date:</b> 20 June 1996 (20.06.96) <b>(30) Priority Data:</b> 60/000,352 20 June 1995 (20.06.95) US 08/567,817 6 December 1995 (06.12.95) US <b>(71) Applicant:</b> INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US). <b>(72) Inventors:</b> COLEMAN, Roger; 260 Mariposa #2, Mountain View, CA 94041 (US). GUEGLER, Karl, J.; 1048 Oakland Avenue, Menlo Park, CA 94025 (US). AU-YOUNG, Janice; 1419 Kains Avenue, Berkeley, CA 94702 (US). BANDMAN, Olga; 2309 Rock Street #27, Mountain View, CA 94043 (US). SEILHAMER, Jeffrey, J.; 12555 La Cresta, Los Altos Hills, CA 94022 (US). <b>(74) Agent:</b> GLAISTER, Debra, J.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).		<b>(81) Designated States:</b> AT, AU, BR, CA, CH, CN, DE, DK, ES, FI, GB, IL, JP, KR, MX, NO, NZ, RU, SE, SG, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>  <b>(88) Date of publication of the international search report:</b> 20 March 1997 (20.03.97)	

**(54) Title:** A HUMAN EDG-2 RECEPTOR HOMOLOG**(57) Abstract**

The present invention provides nucleic acid and amino acid sequences that identify and encode a novel EDG-2 receptor homolog (hedg) expressed in human rheumatoid synovium. The present invention also provides for probes for the detection of nucleotide sequences encoding of HEDG or HEDG-like molecules, antisense molecules to the nucleotide sequences which encode HEDG, diagnostic tests based on HEDG encoding nucleic acid molecules, genetically engineered expression vectors and host cells for the production of purified HEDG, antibodies capable of binding specifically to HEDG, and antagonists and inhibitors with specific binding activity for the polypeptide HEDG.

1 23 35 47 59 71 83 95 107 119 131 143 155 167 179 191 203 215 227 239 251 263 275 287 299 311 323 335 347 359 371 383 395 407 419 431 443 455 467 479 491 503 515 527 539 551 563 575 587 599 611 623 635 647 659 671 683 695 707 719 731 743 755 767 779 791 803 815 827 839 851 863 875 887 899 911 923 935 947 959 971 983 995 1007 1019 1031 1043 1055 1067 1079 1091 1103 1115 1127 1139 1151 1163 1175 1187 1199 1211 1223 1235 1247 1259 1271 1283 1295 1307 1319 1331 1343 1355 1367 1379 1391 1403 1415 1427 1439 1451 1463 1475 1487 1499 1511 1523 1535 1547 1559 1571 1583 1595 1607 1619 1631 1643 1655 1667 1679 1691 1703 1715 1727 1739 1751 1763 1775 1787 1799 1811 1823 1835 1847 1859 1871 1883 1895 1907 1919 1931 1943 1955 1967 1979 1991 2003 2015 2027 2039 2051 2063 2075 2087 2099 2111 2123 2135 2147 2159 2171 2183 2195 2207 2219 2231 2243 2255 2267 2279 2291 2303 2315 2327 2339 2351 2363 2375 2387 2399 2411 2423 2435 2447 2459 2471 2483 2495 2507 2519 2531 2543 2555 2567 2579 2591 2603 2615 2627 2639 2651 2663 2675 2687 2699 2711 2723 2735 2747 2759 2771 2783 2795 2807 2819 2831 2843 2855 2867 2879 2891 2903 2915 2927 2939 2951 2963 2975 2987 2999 3011 3023 3035 3047 3059 3071 3083 3095 3107 3119 3131 3143 3155 3167 3179 3191 3203 3215 3227 3239 3251 3263 3275 3287 3299 3311 3323 3335 3347 3359 3371 3383 3395 3407 3419 3431 3443 3455 3467 3479 3491 3503 3515 3527 3539 3551 3563 3575 3587 3599 3611 3623 3635 3647 3659 3671 3683 3695 3707 3719 3731 3743 3755 3767 3779 3791 3803 3815 3827 3839 3851 3863 3875 3887 3899 3911 3923 3935 3947 3959 3971 3983 3995 4007 4019 4031 4043 4055 4067 4079 4091 4103 4115 4127 4139 4151 4163 4175 4187 4199 4211 4223 4235 4247 4259 4271 4283 4295 4307 4319 4331 4343 4355 4367 4379 4391 4403 4415 4427 4439 4451 4463 4475 4487 4499 4511 4523 4535 4547 4559 4571 4583 4595 4607 4619 4631 4643 4655 4667 4679 4691 4703 4715 4727 4739 4751 4763 4775 4787 4799 4811 4823 4835 4847 4859 4871 4883 4895 4907 4919 4931 4943 4955 4967 4979 4991 5003 5015 5027 5039 5051 5063 5075 5087 5099 5111 5123 5135 5147 5159 5171 5183 5195 5207 5219 5231 5243 5255 5267 5279 5291 5303 5315 5327 5339 5351 5363 5375 5387 5399 5411 5423 5435 5447 5459 5471 5483 5495 5507 5519 5531 5543 5555 5567 5579 5591 5603 5615 5627 5639 5651 5663 5675 5687 5699 5711 5723 5735 5747 5759 5771 5783 5795 5807 5819 5831 5843 5855 5867 5879 5891 5903 5915 5927 5939 5951 5963 5975 5987 5999 6011 6023 6035 6047 6059 6071 6083 6095 6107 6119 6131 6143 6155 6167 6179 6191 6203 6215 6227 6239 6251 6263 6275 6287 6299 6311 6323 6335 6347 6359 6371 6383 6395 6407 6419 6431 6443 6455 6467 6479 6491 6503 6515 6527 6539 6551 6563 6575 6587 6599 6611 6623 6635 6647 6659 6671 6683 6695 6707 6719 6731 6743 6755 6767 6779 6791 6803 6815 6827 6839 6851 6863 6875 6887 6899 6911 6923 6935 6947 6959 6971 6983 6995 7007 7019 7031 7043 7055 7067 7079 7091 7103 7115 7127 7139 7151 7163 7175 7187 7199 7211 7223 7235 7247 7259 7271 7283 7295 7307 7319 7331 7343 7355 7367 7379 7391 7403 7415 7427 7439 7451 7463 7475 7487 7499 7511 7523 7535 7547 7559 7571 7583 7595 7607 7619 7631 7643 7655 7667 7679 7691 7703 7715 7727 7739 7751 7763 7775 7787 7799 7811 7823 7835 7847 7859 7871 7883 7895 7907 7919 7931 7943 7955 7967 7979 7991 8003 8015 8027 8039 8051 8063 8075 8087 8099 8111 8123 8135 8147 8159 8171 8183 8195 8207 8219 8231 8243 8255 8267 8279 8291 8303 8315 8327 8339 8351 8363 8375 8387 8399 8411 8423 8435 8447 8459 8471 8483 8495 8507 8519 8531 8543 8555 8567 8579 8591 8603 8615 8627 8639 8651 8663 8675 8687 8699 8711 8723 8735 8747 8759 8771 8783 8795 8807 8819 8831 8843 8855 8867 8879 8891 8903 8915 8927 8939 8951 8963 8975 8987 8999 9011 9023 9035 9047 9059 9071 9083 9095 9107 9119 9131 9143 9155 9167 9179 9191 9203 9215 9227 9239 9251 9263 9275 9287 9299 9311 9323 9335 9347 9359 9371 9383 9395 9407 9419 9431 9443 9455 9467 9479 9491 9503 9515 9527 9539 9551 9563 9575 9587 9599 9611 9623 9635 9647 9659 9671 9683 9695 9707 9719 9731 9743 9755 9767 9779 9791 9803 9815 9827 9839 9851 9863 9875 9887 9899 9911 9923 9935 9947 9959 9971 9983 9995 10007 10019 10031 10043 10055 10067 10079 10091 10103 10115 10127 10139 10151 10163 10175 10187 10199 10211 10223 10235 10247 10259 10271 10283 10295 10307 10319 10331 10343 10355 10367 10379 10391 10403 10415 10427 10439 10451 10463 10475 10487 10499 10511 10523 10535 10547 10559 10571 10583 10595 10607 10619 10631 10643 10655 10667 10679 10691 10703 10715 10727 10739 10751 10763 10775 10787 10799 10811 10823 10835 10847 10859 10871 10883 10895 10907 10919 10931 10943 10955 10967 10979 10991 11003 11015 11027 11039 11051 11063 11075 11087 11099 11111 11123 11135 11147 11159 11171 11183 11195 11207 11219 11231 11243 11255 11267 11279 11291 11303 11315 11327 11339 11351 11363 11375 11387 11399 11411 11423 11435 11447 11459 11471 11483 11495 11507 11519 11531 11543 11555 11567 11579 11591 11603 11615 11627 11639 11651 11663 11675 11687 11699 11711 11723 11735 11747 11759 11771 11783 11795 11807 11819 11831 11843 11855 11867 11879 11891 11903 11915 11927 11939 11951 11963 11975 11987 11999 12011 12023 12035 12047 12059 12071 12083 12095 12107 12119 12131 12143 12155 12167 12179 12191 12203 12215 12227 12239 12251 12263 12275 12287 12299 12311 12323 12335 12347 12359 12371 12383 12395 12407 12419 12431 12443 12455 12467 12479 12491 12503 12515 12527 12539 12551 12563 12575 12587 12599 12611 12623 12635 12647 12659 12671 12683 12695 12707 12719 12731 12743 12755 12767 12779 12791 12803 12815 12827 12839 12851 12863 12875 12887 12899 12911 12923 12935 12947 12959 12971 12983 12995 13007 13019 13031 13043 13055 13067 13079 13091 13103 13115 13127 13139 13151 13163 13175 13187 13199 13211 13223 13235 13247 13259 13271 13283 13295 13307 13319 13331 13343 13355 13367 13379 13391 13403 13415 13427 13439 13451 13463 13475 13487 13499 13511 13523 13535 13547 13559 13571 13583 13595 13607 13619 13631 13643 13655 13667 13679 13691 13703 13715 13727 13739 13751 13763 13775 13787 13799 13811 13823 13835 13847 13859 13871 13883 13895 13907 13919 13931 13943 13955 13967 13979 13991 14003 14015 14027 14039 14051 14063 14075 14087 14099 14111 14123 14135 14147 14159 14171 14183 14195 14207 14219 14231 14243 14255 14267 14279 14291 14303 14315 14327 14339 14351 14363 14375 14387 14399 14411 14423 14435 14447 14459 14471 14483 14495 14507 14519 14531 14543 14555 14567 14579 14591 14603 14615 14627 14639 14651 14663 14675 14687 14699 14711 14723 14735 14747 14759 14771 14783 14795 14807 14819 14831 14843 14855 14867 14879 14891 14903 14915 14927 14939 14951 14963 14975 14987 14999 15011 15023 15035 15047 15059 15071 15083 15095 15107 15119 15131 15143 15155 15167 15179 15191 15203 15215 15227 15239 15251 15263 15275 15287 15299 15311 15323 15335 15347 15359 15371 15383 15395 15407 15419 15431 15443 15455 15467 15479 15491 15503 15515 15527 15539 15551 15563 15575 15587 15599 15611 15623 15635 15647 15659 15671 15683 15695 15707 15719 15731 15743 15755 15767 15779 15791 15803 15815 15827 15839 15851 15863 15875 15887 15899 15911 15923 15935 15947 15959 15971 15983 15995 16007 16019 16031 16043 16055 16067 16079 16091 16103 16115 16127 16139 16151 16163 16175 16187 16199 16211 16223 16235 16247 16259 16271 16283 16295 16307 16319 16331 16343 16355 16367 16379 16391 16403 16415 16427 16439 16451 16463 16475 16487 16499 16511 16523 16535 16547 16559 16571 16583 16595 16607 16619 16631 16643 16655 16667 16679 16691 16703 16715 16727 16739 16751 16763 16775 16787 16799 16811 16823 16835 16847 16859 16871 16883 16895 16907 16919 16931 16943 16955 16967 16979 16991 17003 17015 17027 17039 17051 17063 17075 17087 17099 17111 17123 17135 17147 17159 17171 17183 17195 17207 17219 17231 17243 17255 17267 17279 17291 17303 17315 17327 17339 17351 17363 17375 17387 17399 17411 17423 17435 17447 17459 17471 17483 17495 17507 17519 17531 17543 17555 17567 17579 17591 17603 17615 17627 17639 17651 17663 17675 17687 17699 17711 17723 17735 17747 17759 17771 17783 17795 17807 17819 17831 17843 17855 17867 17879 17891 17903 17915 17927 17939 17951 17963 17975 17987 17999 18011 18023 18035 18047 18059 18071 18083 18095 18107 18119 18131 18143 18155 18167 18179 18191 18203 18215 18227 18239 18251 18263 18275 18287 18299 18311 18323 18335 18347 18359 18371 18383 18395 18407 18419 18431 18443 18455 18467 18479 18491 18503 18515 18527 18539 18551 18563 18575 18587 18599 18611 18623 18635 18647 18659 18671 18683 18695 18707 18719 18731 18743 18755 18767 18779 18791 18803 18815 18827 18839 18851 18863 18875 18887 18899 18911 18923 18935 18947 18959 18971 18983 18995 19007 19019 19031 19043 19055 19067 19079 19091 19103 19115 19127 19139 19151 19163 19175 19187 19199 19211 19223 19235 19247 19259 19271 19283 19295 19307 19319 19331 19343 19355 19367 19379 19391 19403 19415 19427 19439 19451 19463 19475 19487 19499 19511 19523 19535 19547 19559 19571 19583 19595 19607 19619 19631 19643 19655 19667 19679 19691 19703 19715 19727 19739 19751 19763 19775 19787 19799 19811 19823 19835 19847 19859 19871 19883 19895 19907 19919 19931 19943 19955 19967 19979 19991 20003 20015 20027 20039 20051 20063 20075 20087 20099 20111 20123 20135 20147 20159 20171 20183 20195 20207 20219 20231 20243 20255 20267 20279 20291 20303 20315 20327 20339 20351 20363 20375 20387 20399 20411 20423 20435 20447 20459 20471 20483 20495 20507 20519 20531 20543 20555 20567 20579 20591 20603 20615 20627 20639 20651 20663 20675 20687 20699 20711 20723 20735 20747 20759 20771 20783 20795 20807 20819 20831 20843 20855 20867 20879 20891 20903 20915 20927 20939 20951 20963 20975 20987 20999 21011 21023 21035 21047 21059 21071 21083 21095 21107 21119 21131 21143 21155 21167 21179 21191 21203 21215 21227 21239 21251 21263 21275 21287 21299 21311 21323 21335 21347 21359 21371 21383 21395 21407 21419 21431 21443 21455 21467 21479 21491 21503 21515 21527 21539 21551 21563 21575 21587 21599 21611 21623 21635 21647 21659 21671 21683 21695 21707 21719 21731 21743 21755 21767 21779 21791 21803 21815 21827 21839 21851 21863 21875 21887 21899 21911 21923 21935 21947 21959 21971 21983 21995 22007 22019 22031 22043 22055 22067 22079 22091 22103 22115 22127 22139 22151 22163 22175 22187 22199 22211 22223 22235 22247 22259 22271 22283 22295 22307 22319 22331 22343 22355 22367 22379 22391 22403 22415 22427 22439 22451 22463 22475 22487 22499 22511 22523 22535 22547 22559 22571 22583 22595 22607 22619 22631 22643 22655 22667 22679 22691 22703 22715 22727 22739 22751 22763 22775 22787 22799 22811 22823 22835 22847 22859 22871 22883 22895 22907 22919 22931 22943 22955 22967 22979 22991 23003 23015 23027 23039 23051 23063 23075 23087 23099 23111 23123 23135 23147 23159 23171 23183 23195 23207 23219 23231 23243 23255 23267 23279 23291 23303 23315 23327 23339 23351 23363 23375 23387 23399 23411 23423 23435 23447 23459 23471 23483 23495 23507 23519 23531 23543 23555 23567 23579 23591 23603 23615 23627 23639 23651 23663 23675 23687 23699 23711 23723 23735 23747 23759 23771 23783 23795 23807 23819 23831 23843 23855 23867 23879 23891 23903 2

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Larvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## INTERNATIONAL SEARCH REPORT

Inter. Application No  
PC1/US 96/10618

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C07K14/705 C07K16/18 C12N15/11 C12N5/10  
G01N33/53 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EMBL database Accession number U18405 28-12-1994 XP002024555 see the whole document	1,2,8-11
Y	--- CELL, APR 5 1991, 65 (1) P175-87, UNITED STATES, XP002024553 BUCK L ET AL: "A novel multigene family may encode odorant receptors: a molecular basis for odor recognition." see page 185, right-hand column, paragraph 3 - page 186, left-hand column, paragraph 4 --- -/-	1,2,8,11

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*A\* document member of the same patent family

Date of the actual completion of the international search

4 February 1997

Date of mailing of the international search report

12.02.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Gurdjian, D

## INTERNATIONAL SEARCH REPORT

Inter national Application No  
PCT/US 96/10618

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	GENE, MAR 10 1995, 154 (2) P265-9, NETHERLANDS, XP002024554 BARHAM GJ ET AL: "Cloning and expression of a cDNA encoding ovine interleukin 7." see the whole document ---	1,2,8-11
A	WO 91 15583 A (AMERICAN NAT RED CROSS) 17 October 1991 see the whole document ---	1,2,8-11
A	BIOCHIM BIOPHYS ACTA, JAN 25 1995, 1260 (2) P227-9, NETHERLANDS, XP000609651 HLA T ET AL: "Characterization of edg-2, a human homologue of the Xenopus maternal transcript G10 from endothelial cells." see the whole document ---	1,2,8-11
P,X	RECEPTORS CHANNELS, 1995, 3 (4) P255-62, SWITZERLAND, XP000610109 MASANA MI ET AL: "Cloning and characterization of a new member of the G-protein coupled receptor EDG family." see the whole document ---	1,2,8-11
T	SWISSPROT DATABASE Accession number P46628 01-11-1995 XP002024556 see the whole document -----	1,2,8-11



# INTERNATIONAL SEARCH REPORT

ernational application No.

PCT/US 96/ 10618

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 5, 14, 20  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although these claims are directed to a method of treatment of the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## PC1/US 96/10618

Form PCT ISA '210 (patent family annex) (July 1992)